Jesalis

Jesalis Pharma is a specialty pharmaceutical company headquartered in Garching, Germany, dedicated to the development and commercialization of therapies for rare diseases. The company focuses primarily on metabolic disorders, offering a portfolio of orphan drugs that address significant unmet medical needs. Key products in its commercial portfolio include Pheburane for the treatment of urea cycle disorders and Nityr for hereditary tyrosinemia type 1. Jesalis Pharma operates as a strategic partner for international biotech firms, providing expertise in regulatory affairs, market access, and distribution within the European market, particularly the DACH region. By focusing on niche indications, the company ensures that patients with rare conditions have access to essential, life-improving medications.